Streetbeat News

Price Targets

ACAD

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on ACADIA Pharmaceuticals (ACAD) and maintained a $42 price target.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 3:13 pm

ELV

Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Elevance Health (NYSE:ELV) and maintained a price target of $547.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 3:09 pm

INTC

Cantor Fitzgerald analyst C J Muse has reiterated a Neutral rating on Intel (NASDAQ:INTC) and maintained a $50 price target.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 3:05 pm

SNOW

Snowflake's stock price increased following an upgrade by Raymond James, which raised its price target from $190 to $223.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 3:02 pm

MTSI

MACOM Technology Solutions (NASDAQ:MTSI) has received mixed analyst ratings over the last three months, with a shift towards more bullish perspectives in recent evaluations. The average 12-month price target for MTSI has been raised to $94.83, indicating a 10.91% increase from the previous target of $85.50. Analysts from firms like Needham, Barclays, and Piper Sandler have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Despite these optimistic analyst ratings, MACOM faces challenges such as lower market capitalization, revenue decline of -15.59% as of September 30, 2023, below-average net margin, ROE, ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 3:00 pm

AFL

Aflac (NYSE:AFL) has received mixed analyst ratings over the past three months, with a recent shift towards more positive evaluations. The average 12-month price target for Aflac has been raised to $81.00, up from $75.00, indicating an 8.0% increase. Analysts from firms like Raymond James, UBS, Goldman Sachs, Evercore ISI Group, and Morgan Stanley have adjusted their ratings and price targets, reflecting a nuanced view of Aflac's market position and financial performance. Aflac's financial indicators, such as market capitalization, revenue growth, net margin, ROE, ROA, and debt management, underscore its robust market position and financial health.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 3:00 pm

SNOW

Snowflake (NYSE:SNOW) has received diverse analyst ratings over the past quarter, with a recent shift towards more bullish sentiments. The average 12-month price target for SNOW has increased to $214.62, reflecting an 8.75% rise from the previous target. Analysts from firms like Raymond James, JMP Securities, and Truist Securities have adjusted their ratings and price targets, indicating a positive outlook on Snowflake's performance. Snowflake's financials show solid revenue growth and strong financial management despite a below-average net margin and ROA.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 3:00 pm

COUR

Cantor Fitzgerald analyst Brett Knoblauch maintains an Overweight rating on Coursera (NYSE:COUR) and raises the price target from $22 to $26.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 2:55 pm

CRNX

Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Crinetics Pharmaceuticals (CRNX) and maintained a $50 price target.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 2:52 pm

CRWD

Cantor Fitzgerald analyst Yi Fu Lee has reiterated an Overweight rating on CrowdStrike Holdings (CRWD) and maintained a price target of $240.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 2:48 pm